YENİ TANILI AKUT MİYELOBLASTİK LÖSEMİ HASTALARINDA HASTALIK ÖZELLİKLERİ VE TEDAVİ SONUÇLARINI ETKİLEYEN FAKTÖRLER: TEK MERKEZ DENEYİMİ

Öz

Giriş: Akut lösemi tedavisi ile ilgili klinik çalışmalara genellikle önemli komorbiditeleri olmayan hastalar alınmaktadır. Bu nedenle literatürde bildirilen tedavi sonuçları gerçek hayattaki klinik gerçeklerle bağdaşmayabilmektedir. Gereç ve yöntem: Ocak 2003 ile Aralık 2008 tarihleri arasına ünitemizde yeni tanı konulan 147 AML hastası retrospektif olarak incelenmiştir. Hastaların ortanca yaşı 48 (16-85), 11 (%7,5) tanesi CBF tipi AML, 18 (%12,2) tanesi APL ve 118 (%80,3) tanesini de diğer AML hastaları oluşturmaktaydı. AML hastalarının %74,8’ine idarubisin-sitarabin (3+7), %13,6’sına mitoksantronsitarabin (3+7), %2,9’una yüksek doz sitarabin-mitoksantron, %0,9’una sitarabin, %0,9’una etoposid-mitoksantron-sitarabin, %1,9’una idarubisin-sitarabin (2+5) ve %4,8’ine (akut promiyelositik lösemi hastaları) modifiye AIDA kemoterapi protokolü verildi. Bulgular: Ortalama hemoglobin, beyaz küre ve trombosit değerleri sırasıyla 8,6 g/dl (3,5-14), 41 359/mm3 (600-300,000) ve 64,086/mm3 (3000-459,000) idi. Toplam 12 (%8,1) hastaya allojeneik kök hücre nakli uygulanmıştı. İndüksiyon tedavisi ile %52,4 tam yanıt, %27,2 indüksiyon esnasında eks ve %5,4 oranında da yanıtsız olarak bulundu. Tüm hastaların 5,9 yıllık total sağkalım oranı %29 ve indüksiyonla remisyon sağlanan hastalarda 5 yıllık hastalıksız sağkalım oranı %44 idi. Sonuç: Tam yanıtı etkileyen faktörler sırasıyla yaş ve ECOG performans durumu bulundu. Total sağkalımı etkileyen faktörler ise yaş (≤30 yaş %32 sağkalım, 30-59 yaş %37, ≥60 yaş %13, p= 0,003), ECOG performansı (ECOG≤1 %33 sağkalım, ECOG>1 %17, p= 0,001) ve AML tipi (CBF tipi AML’de %72 sağkalım, APL hastalarında %41, diğer AML hastalarında %24, p= 0,043) olarak bulundu. Çok değişkenli analiz yapıldığında sadece ECOG performans durumu anlamlı değişken olarak bulunmuştur (p=0,003).

Anahtar Kelimeler

• Erişkin akut miyeloblastik lösemi, total sağkalım, hastalıksız sağkalım

Kaynakça

1. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S. Randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 87 :1710–1717, 1996.
2. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, Whiteside MG, Kronenberg H, Ma D, Dodds A. Etoposide in acute non-lymphoblastic leukemia. Blood 75 :27-32, 1990.
3. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 15;58 :4173-4179, 1998.
4. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B (CALGB 8461). Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 100:4325-4336, 2002.
5. Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Davey F, Schiffer CA, Bloomfield CD. Patients with t(8;21) (q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 17 :3767-3775, 1999.
6. Cartwright RA, Alexander FE, Mc Kinney PA, Ricketts TJ. Leukemia and Lymphoma: An Atlas of Distribution within Areas of England and Wales 1984-88. Leukemia Research Fund, London. 1990.
7. De Angelo DJ, Stone RM, Durrant S, Liu D, Baccarani M, Schiffer CA. Gemtuzumab ozogamicin (Mylotarg®) in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: two age- specific phase II trials [abstract]. Blood 102:100a 2003.
8. Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, Kopel S, Preisler H, McIntyre OR, Schiffer C. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood. 7 :2520-2526, 1991.

9. Gilliland DG, Griffin JD. The role of FLT3 in hematopoiesis and leukemia. Blood. 100 :1332-1342, 2002.
10. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 92 :2322-2333, 1998.
11. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH; Medical Research Council Adult Leukemia Working Party. The classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 98 :1312-1320, 2001. of hierarchical cytogenetic
12. Hann IM, Stevens RF, Goldstone A, Rees JKH, Wheatley K, Gray RG. Randomized comparison of DAT versus ADE as induction chemotherapy in children and young adults with acute myeloid leukemia. Results of the medical research council’s 10th AML Trial (MRC AML 10). Blood. 89 :2311-2318, 1997.
13. Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE. Hematology Basic Principles and Practice. Chapter 60: Clinical manifestations of acute myeloid leukemia. Hematology Basic Principles and Practice. 1071- 1097, Basic Principles and Practice of Hematology, 2009.
14. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, Velez-Garcia E, Moore JO, Shea TC, Hoke E, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA; Cancer and Leukemia Group B. Dose escalation studies of Ara-C (A), daunorubicin (D) and etoposide (E) with and without multidrug resistance (MDR) Modulation with PSC- 833 in untreated adults with acute myeloid leukemia (AML) younger than 60 years: final induction results of Cancer an Leukemia Group B Study 9621. J Clin Oncol. 22 :4290- 4301, 2004.
15. Poppe B, Vandesompele J, Schoch C, Lindvall C, Mrozek K, Bloomfield CD, Beverloo HB, Michaux L, Dastugue N, Herens C, Yigit N, De Paepe A, Hagemeijer A, Speleman F. Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloidmalignancies. Blood.103:229- 235, 2004.
16. Preisler H, Davis RB, Kirshner J, Dupre E, Richards F, Hoagland HC, Kopel S, Levy RN, Carey R, Schulman P. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood. 69 :1441–1449, 1987.
17. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 86:457-462, 1995.
18. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, Liesveld JL, Abboud CN, Dewald G, Hayes FA, Tallman MS, Wiernik PH; Eastern Cooperative Oncology. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 103:479-485, 2004.
19. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR; Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 19 :3244-3254, 2001.
20. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood96 :4075-4083, 2000.
21. Tallman MS, Rowlings PA, Milone G, Zhang MJ, Perez WS, Weisdorf D, Keating A, Gale RP, Geller RB, Laughlin MJ, Lazarus HM, Luger SM, McCarthy PL, Rowe JM, Saez RA, Vowels MR, Horowitz MM. Effect of postremission chemotherapy before human leukocyte antigen-identical myelogenous leukemia in first complete remission. Blood. 96 :1254-1258, 2000.
22. transplantation for acute
23. Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 102 :1578-1582, 2003.
24. Wang XQ. Sino-US Shanghai Leukemia Cooperative Group. Distribution of WHO subtypes, initial treatment outcomes and prognosis study of 623 unselected adult patients with acute myeloid leukaemia in Shanghai. Zhonghua Xue Ye Xue Za Zhi. 31 :102-107, 2010.
25. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M. A randomized investigation of high-dose versus Standard-dose cytosine arabinoside with daunorubicin in 100 patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 88:2841–2851, 1996.